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People fear diseases such as Ebola, Marburg, Lassa fever, and rabies, for good reason; they have high mortality rates and few, if any, possible treatments. Up to 90 percent of people who contract Ebola, for 
instance, die of the disease.
These diseases are zoonoses—infections that can be passed 
between humans and animals. Humans can contract Lassa 
fever and rabies directly from animals, and Ebola, Marburg, 
and HIV are all believed to have originated in animals. It’s 
likely that the recent Ebola outbreak in West Africa, as with 
previous outbreaks of the disease, arose when a person or 
community came into contact with an infected great ape. 
Committed to taking a One Health perspective, and 
facing a gaping need for therapies against these life-
threatening ailments, researchers at the University of 
Pennsylvania School of Veterinary Medicine have been 
applying their expertise in infectious diseases toward 
understanding the molecular workings of these viruses. 
Their research is helping identify ways to exploit the 
microbes’ own sinister strategies to effectively stop the 
pathogens in their tracks. 
Penn Vet’s Dr. Ronald N. Harty, an associate professor 
of microbiology, recently teamed with colleagues to identify 
and develop compounds that can reduce the ability of a 
virus to spread infection. Reporting their findings in two 
studies published in the Journal of Virology, Harty and his team 
rounded up several prototypic compounds with the potential 
to one day serve as broad-spectrum anti-viral drugs. 
Viruses can be powerful agents of disease, but they are 
relatively powerless on their own. In order to reproduce, 
they must take over host cell proteins and machinery. When 
they’re ready to exit the cell, they again use host molecules 
in the cell membrane in a process called “budding.” Then 
they move on to other cells, spreading infection.
“What happens is the virus actually hijacks or recruits 
different host proteins and host functions and makes use of 
those proteins to efficiently get out of the cell,” Harty said.  
It is this step that has captured the interest of Harty and 
colleagues in recent years. In their two new reports, they 
have zeroed in on the budding process, attempting to block 
it and reduce viral infections to a level a person’s immune 
system would be able to control more easily.
In the first paper, the researchers examined the 
interaction between the human protein Tsg101 and the 
viral protein sequence known as PTAP, which is present 
in proteins that play important roles in the budding of 
Ebola and HIV. This interplay is important for the virus to 
break free of the host cell’s plasma membrane and continue 
infecting other cells. If this interaction is blocked, many 
of the viruses will remain tethered to the cell membrane, 
unable to bud out and perpetuate the infection.
Though the viruses under study are too dangerous to 
manipulate in the Penn Vet lab, which is a Biosafety Level-
II (BSL-II) facility, Harty’s team was nonetheless able to 
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looking at what are known as virus-like particles, or VLPs. VLPs 
cannot infect cells, but are useful for studying viral proteins. 
In this case, the researchers produced VLPs using a Junin 
viral matrix protein of which PTAP is a part. The pathogenic 
strain of Junin virus causes Argentine hemorrhagic fever and is 
considered a potential bioterrorism agent.
Harty’s team used the VLPs to screen dozens and dozens of 
small molecules to find some that would block the interaction 
between Tsg101 and PTAP. A promising candidate emerged 
called compound 0013.
Testing the effectiveness of this molecule in their VLP assay, 
the team found that it reduced the ability of the Junin VLP to 
bud off from human cells in culture by more than 90 percent. 
It was similarly effective against proteins that are found in Ebola 
and HIV.
As a final confirmation of the compound’s potential to stop 
a virus from spreading, they tested it against an actual virus: the 
nonpathogenic vaccine strain of the Junin virus. The researchers 
found that it significantly decreased viral budding in a dose-
dependent manner. 
The second paper used an analogous strategy to try to block 
another host-virus interaction, this time examining the viral 
protein sequence called PPxY—found in the matrix proteins 
of Marburg, Ebola, and rabies viruses as well as a host of other 
dangerous pathogens. PPxY interacts with an enzyme in human 
cells called Nedd4 during budding.
Again, after screening many small molecules to see which 
would best inhibit the PPxY-Nedd4 interaction, the team found 
two strong candidate molecules. Further testing showed that 
these two molecules could effectively inhibit budding of rabies 
virus, Marburg VLPs, and other PPxY-containing viruses. 
Reining in budding even by a fraction could significantly 
decrease the likelihood that an infection will get out of control. 
According to Harty, “By slowing down virus budding, we may 
allow an individual’s immune system a chance to develop a 
robust and protective response.”
With further testing, the compounds that Harty has 
pinpointed may one day serve as important anti-viral therapies. 
Drugs that target host-virus interactions, such as the proteins 
involved in budding, have a distinct advantage over drugs that 
target viral proteins only: they make it difficult for a virus to 
mutate in such a way that it would develop resistance against the 
treatment.
“If it did that, the virus would be compromising its own 
ability to exit the cell and continue spreading infection,” Harty 
explained.
However, a focus on the host side also comes with a potential 
drawback: the possibility that a drug might compromise the 
normal function of the protein. Further refinement of the drugs 
could reduce this possibility, but when dealing with severe 
diseases such as Ebola and Argentine hemorrhagic fever, the 
benefits of treating an otherwise fatal condition would outweigh 
potential side effects, Harty said.
These drugs could also be offered in a cocktail with additional 
compounds that block other stages of the virus life cycle, further 
amplifying their power. The next steps for these potential anti-
virals will be to test them in animal models.
For Harty and his team of researchers, the potential clinical 
relevance of these early findings is especially rewarding.
“The main reason we’re excited is that if we can come up 
with something that’s effective, it could have a very broad-
spectrum appeal,” Harty said. In addition to serving people 
worldwide, more effective anti-viral treatments “would give us 
a great way to protect the military, government workers, or first 
responders from these very dangerous diseases.”
Harty collaborated with Penn Vet’s Jianhong Lu, Ziying Han, 
Yuliang Liu, Wenbo Liu, Gordon Ruthel, and Bruce D. Freedman 
and U.S. Army Medical Research Institute of Infectious Disease 
scientists Michael S. Lee and Mark A. Olson on both studies. On the 
second paper, the team was expanded to include Benjamin Davis 
and Matthias J. Schnell of Thomas Jefferson University and Jay E. 
Wrobel and Allen B. Reitz of Fox Chase Chemical Diversity Center.
The research was supported in part by the National Institute of 
Allergy and Infectious Diseases.
From left to right: Budding of the Ebola virus VP40 protein is shown in green.  Cell background is shown in red. Electron 
micrograph of virus particles tethered to the plasma membrane of the cell. Our budding inhibitors function by promoting 
this tethered phenotype and preventing the virus from “pinching off” from the cell membrane and spreading to other cells. 
Ebola (Zaire strain) VP40 protein budding from cells as VLPs (virus-like particles shown in green). Cellular actin is shown in 
red, and cell nuclei are shown in blue.
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